Literature DB >> 8541159

von Willebrand factor and its relevance to cardiovascular disorders.

G Y Lip1, A D Blann.   

Abstract

In the past decade the importance of the vascular endothelium in cardiovascular pathophysiology has become more apparent. One substance that is synthesised by and stored in endothelial cells is von Willebrand factor (vWF). When released, vWF seems to mediate platelet aggregation and adhesion to the vascular endothelium. Because the release of vWF is increased when endothelial cells are damaged, vWF has been proposed as an indicator of endothelial disturbance or dysfunction. The availability of such an index of endothelial dysfunction may have clinical value, because measurement of such a marker can be a non-invasive way of assisting in diagnosis or as an indicator of disease progression. The known association between vWF, thrombogenesis, and atherosclerotic vascular disease also suggests that high concentrations of vWF may be an indirect indicator of atherosclerosis and/or thrombosis. In addition, high vWF concentrations have prognostic implications in patients with ischaemic heart disease and peripheral vascular disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8541159      PMCID: PMC484109          DOI: 10.1136/hrt.74.6.580

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  25 in total

1.  The endothelium. Target and promoter of hypertension?

Authors:  T F Lüscher
Journal:  Hypertension       Date:  1990-05       Impact factor: 10.190

2.  Relationship between factor XII, von Willebrand factor and postoperative deep vein thrombosis.

Authors:  T Nilsson; G Mellbring; U Hedner
Journal:  Acta Chir Scand       Date:  1986-05

3.  Letter: Factor-VIII complex and endothelial damage.

Authors:  B Boneu; M Abbal; J Plante; R Bierme
Journal:  Lancet       Date:  1975-06-28       Impact factor: 79.321

4.  von Willebrand factor abnormalities in primary pulmonary hypertension.

Authors:  R L Geggel; A C Carvalho; L W Hoyer; L M Reid
Journal:  Am Rev Respir Dis       Date:  1987-02

5.  The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group.

Authors:  M Cortellaro; C Boschetti; E Cofrancesco; C Zanussi; M Catalano; G de Gaetano; L Gabrielli; B Lombardi; G Specchia; L Tavazzi
Journal:  Arterioscler Thromb       Date:  1992-09

6.  Antioxidants, von Willebrand factor and endothelial cell injury in hypercholesterolaemia and vascular disease.

Authors:  A D Blann; S R Maxwell; G Burrows; J P Miller
Journal:  Atherosclerosis       Date:  1995-08       Impact factor: 5.162

7.  Platelet function tests in thrombotic cerebrovascular disorders.

Authors:  S Uchiyama; M Takeuchi; M Osawa; I Kobayashi; S Maruyama; M Aosaki; K Hirosawa
Journal:  Stroke       Date:  1983 Jul-Aug       Impact factor: 7.914

8.  Von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarction.

Authors:  F Andreotti; D R Hackett; A W Haider; M C Roncaglioni; G J Davies; J L Beacham; C Kluft; A Maseri
Journal:  Thromb Haemost       Date:  1992-12-07       Impact factor: 5.249

9.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.

Authors:  J H Jansson; T K Nilsson; O Johnson
Journal:  Br Heart J       Date:  1991-11

10.  Lipid peroxidation associated with successful thrombolysis.

Authors:  S W Davies; K Ranjadayalan; D G Wickens; T L Dormandy; A D Timmis
Journal:  Lancet       Date:  1990-03-31       Impact factor: 79.321

View more
  17 in total

1.  Characterization of von Willebrand factor in primary pulmonary hypertension.

Authors:  M T Collados; J Sandoval; S López; F A Massó; A Páez; J R Borbolla; L F Montaño
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

2.  Does telomerase reverse transcriptase induce functional de-differentiation of human endothelial cells?

Authors:  Yvonne Baumer; Dorothee Funk; Burkhard Schlosshauer
Journal:  Cell Mol Life Sci       Date:  2010-03-30       Impact factor: 9.261

3.  Assessment of endothelial function using plasma markers.

Authors:  A Blann; G Lip
Journal:  Heart       Date:  1997-09       Impact factor: 5.994

Review 4.  Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy.

Authors:  G Y Lip
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

5.  Problem behavior of dementia patients predicts low-grade hypercoagulability in spousal caregivers.

Authors:  Roland von Känel; Brent T Mausbach; Joel E Dimsdale; Paul J Mills; Thomas L Patterson; Sonia Ancoli-Israel; Michael G Ziegler; Susan K Roepke; Matthew Allison; Igor Grant
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-05-19       Impact factor: 6.053

6.  Plasma vascular endothelial growth factor, soluble VEGF receptor FLT-1, and von Willebrand factor in glaucoma.

Authors:  P L Lip; D C Felmeden; A D Blann; N Matheou; S Thakur; I A Cunliffe; G Y H Lip
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

7.  Prevalence and Risk Factors Associated With Hypertension in von Willebrand Disease.

Authors:  Mariya H Apostolova; Craig D Seaman; Diane M Comer; Jonathan G Yabes; Margaret V Ragni
Journal:  Clin Appl Thromb Hemost       Date:  2016-09-21       Impact factor: 2.389

8.  Measurement of von Willebrand factor as the marker of endothelial dysfunction in vascular diseases.

Authors:  Beata Horvath; Dalma Hegedus; Laszlo Szapary; Zsolt Marton; Tamas Alexy; Katalin Koltai; Laszlo Czopf; Istvan Wittmann; Istvan Juricskay; Kalman Toth; Gabor Kesmarky
Journal:  Exp Clin Cardiol       Date:  2004

9.  Association of von Willebrand factor blood levels with exercise hypertension.

Authors:  Sonja B Nikolic; Murray J Adams; Petr Otahal; Lindsay M Edwards; James E Sharman
Journal:  Eur J Appl Physiol       Date:  2014-12-25       Impact factor: 3.078

10.  Platelet GPIbalpha, GPIV and vWF polymorphisms and fatal pre-hospital MI among middle-aged men.

Authors:  Minna Pellikka; Lassi Narhi; Markus Perola; Antti Penttila; Pekka J Karhunen; Jussi Mikkelsson
Journal:  J Thromb Thrombolysis       Date:  2007-07-11       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.